Will Cell-Free Production Reshape ADC Manufacturing? "Next-Generation CDMO Technology in the Spotlight"
Simultaneously Improving Cost and Quality with Cell-Free Processes
Stanford Professor Schwartz: "Competitive Edge in High-Precision Production Systems"
"Cell-free production systems allow for protein synthesis in a more precisely controlled environment because there is no need to maintain living cells. This offers significant advantages in terms of both quality consistency and cost reduction."
James Schwartz, a professor at Stanford University in the United States, is answering interview questions at the Korea Society of Biotechnology Spring Conference held at the Yeosu Expo Convention Center in Jeollanam-do on the 9th. Photo by Park Jungyeon
View original imageJames Schwartz, a professor at Stanford University in the United States, discussed the competitiveness of cell-free protein synthesis (CFPS)-based production systems (hereafter referred to as cell-free production systems) at the Korean Society for Biotechnology Spring Conference held at the Yeosu Expo Convention Center in Jeonnam on the 9th.
Cell-free protein synthesis is a technology that produces desired proteins by utilizing only enzymes, without the use of cells. Unlike conventional cell-based production systems, it eliminates the need for a cultivation process and enables precise control over the reaction environment, making it an emerging next-generation technology for biopharmaceutical manufacturing.
Currently, leading biopharmaceutical contract development and manufacturing organizations (CDMOs) such as Samsung Biologics and Celltrion produce antibody drugs primarily using cell-based production systems. Since cell culture, maintenance, and management are required, extended production entails significant costs, and there is a risk of quality variability due to changes in cell conditions.
Cell-free production systems are seen as a technology that could overcome these drawbacks. Professor Schwartz explained, "There is no need for nutrient supply or environmental control to maintain cells, and the protein synthesis process itself can be directly designed and controlled, enabling more consistent quality."
In particular, it is evaluated as having competitive potential in the field of antibody-drug conjugates (ADCs), which has recently attracted the attention of big pharma companies. For ADC therapies, which require precise conjugation between antibodies and drugs, even slight variations in conjugation site or structure can lead to significant differences in efficacy and safety.
The academic community is focusing on the importance of precision at the 'design stage' of proteins due to these characteristics. Cell-free protein synthesis allows for molecular-level control of the reaction environment, making it advantageous for introducing functional groups at specific sites or for precise structural design—areas that are challenging to achieve with conventional cell-based systems.
Another strength of cell-free production systems is cost structure. Professor Schwartz explained that even with small-scale cell-free reactions, it is possible to produce a single dose of high-value gene therapy products. This means that the production process can be simplified while dramatically reducing costs.
He also emphasized the differentiation in terms of quality. In cell-based production, extended cultivation can lead to cell lysis and the generation of impurities, whereas cell-free systems reduce such variables and enable the achievement of more uniform quality.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
However, it is still considered difficult to completely replace existing production systems. Professor Schwartz stated, "With the current level of technology, it is difficult to fully replace cell-based processes in antibody production."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.